Pitavastatin – a new inhibitor of the HMG-CoA reductase: peculiarities of clinical pharmacology and perspectives of its usage in treatment of cardiovascular diseases
Cardiovascular mortality makes up 66.3 % of the total mortality in Ukraine. Myocardial infarction, stroke, atherosclerosis of peripheral arteries are the diseases caused by atherosclerosis and are prevalent in the mortality structure. One of the most effective means of successful prevention of cardi...
Saved in:
| Main Authors: | Dzyak G.V., Yegorov K.Yu., Kolesnik E.L. |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2013-12-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | http://medpers.dsma.dp.ua/issues/2013/N4/36-44.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFICACY OF HMG-CoA REDUCTASE INHIBITORS IN COVID-19 PATIENTS MORTALITY RATE: A META-ANALYSES OF RANDOMIZED CONTROL TRIALS
by: Mohammadreza Shafiei, et al.
Published: (2024-12-01) -
QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition
by: Robert Ancuceanu, et al.
Published: (2024-10-01) -
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.
by: A. E. Berezin, et al.
Published: (2015-06-01) -
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin
by: Berezin A.E., et al.
Published: (2015-06-01) -
Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis
by: Hamdy A. Makhlouf, et al.
Published: (2025-02-01)